Your browser doesn't support javascript.
loading
High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.
Brieger, Katharine K; Phung, Minh Tung; Mukherjee, Bhramar; Bakulski, Kelly M; Anton-Culver, Hoda; Bandera, Elisa V; Bowtell, David D L; Cramer, Daniel W; DeFazio, Anna; Doherty, Jennifer A; Fereday, Sian; Fortner, Renée Turzanski; Gentry-Maharaj, Aleksandra; Goode, Ellen L; Goodman, Marc T; Harris, Holly R; Matsuo, Keitaro; Menon, Usha; Modugno, Francesmary; Moysich, Kirsten B; Qin, Bo; Ramus, Susan J; Risch, Harvey A; Rossing, Mary Anne; Schildkraut, Joellen M; Trabert, Britton; Vierkant, Robert A; Winham, Stacey J; Wentzensen, Nicolas; Wu, Anna H; Ziogas, Argyrios; Khoja, Lilah; Cho, Kathleen R; McLean, Karen; Richardson, Jean; Grout, Bronwyn; Chase, Anne; Deurloo, Cindy McKinnon; Odunsi, Kunle; Nelson, Brad H; Brenton, James D; Terry, Kathryn L; Pharoah, Paul D P; Berchuck, Andrew; Hanley, Gillian E; Webb, Penelope M; Pike, Malcolm C; Pearce, Celeste Leigh.
Afiliação
  • Brieger KK; Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan.
  • Phung MT; Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan.
  • Mukherjee B; Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan.
  • Bakulski KM; Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan.
  • Anton-Culver H; Department of Medicine, School of Medicine, University of California Irvine, Irvine, California.
  • Bandera EV; Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
  • Bowtell DDL; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Cramer DW; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
  • DeFazio A; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Doherty JA; Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Fereday S; Centre for Cancer Research, The Westmead Institute for Medical Research, and The University of Sydney, Westmead, New South Wales, Australia.
  • Fortner RT; Department of Gynaecological Oncology, Westmead Hospital, Westmead, New South Wales, Australia.
  • Gentry-Maharaj A; Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah.
  • Goode EL; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Goodman MT; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
  • Harris HR; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Matsuo K; MRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, UCL, London, United Kingdom.
  • Menon U; Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
  • Modugno F; Cancer Prevention and Genetics Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
  • Moysich KB; Community and Population Health Research Center, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
  • Qin B; Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Ramus SJ; Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington.
  • Risch HA; Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan.
  • Rossing MA; Department of Cancer Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Schildkraut JM; MRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, UCL, London, United Kingdom.
  • Trabert B; Women's Cancer Research Center, Magee-Women's Research Institute and UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
  • Vierkant RA; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
  • Winham SJ; Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania.
  • Wentzensen N; Division of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Wu AH; Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
  • Ziogas A; School of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, New South Wales, Australia.
  • Khoja L; Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
  • Cho KR; Chronic Disease Epidemiology Department, Yale School of Public Health, New Haven, Connecticut.
  • McLean K; Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Richardson J; Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington.
  • Grout B; Emory University Rollins School of Public Health, Atlanta, Georgia.
  • Chase A; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
  • Deurloo CM; Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
  • Odunsi K; Division of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
  • Nelson BH; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
  • Brenton JD; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Terry KL; Department of Medicine, School of Medicine, University of California Irvine, Irvine, California.
  • Pharoah PDP; Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan.
  • Berchuck A; Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan.
  • Hanley GE; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan.
  • Webb PM; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Pike MC; Patient Advocate.
  • Pearce CL; Patient Advocate.
Cancer Epidemiol Biomarkers Prev ; 31(2): 443-452, 2022 02.
Article em En | MEDLINE | ID: mdl-34789471
ABSTRACT

BACKGROUND:

There is suggestive evidence that inflammation is related to ovarian cancer survival. However, more research is needed to identify inflammation-related factors that are associated with ovarian cancer survival and to determine their combined effects.

METHODS:

This analysis used pooled data on 8,147 women with invasive epithelial ovarian cancer from the Ovarian Cancer Association Consortium. The prediagnosis inflammation-related exposures of interest included alcohol use; aspirin use; other nonsteroidal anti-inflammatory drug use; body mass index; environmental tobacco smoke exposure; history of pelvic inflammatory disease, polycystic ovarian syndrome, and endometriosis; menopausal hormone therapy use; physical inactivity; smoking status; and talc use. Using Cox proportional hazards models, the relationship between each exposure and survival was assessed in 50% of the data. A weighted inflammation-related risk score (IRRS) was developed, and its association with survival was assessed using Cox proportional hazards models in the remaining 50% of the data.

RESULTS:

There was a statistically significant trend of increasing risk of death per quartile of the IRRS [HR = 1.09; 95% confidence interval (CI), 1.03-1.14]. Women in the upper quartile of the IRRS had a 31% higher death rate compared with the lowest quartile (95% CI, 1.11-1.54).

CONCLUSIONS:

A higher prediagnosis IRRS was associated with an increased mortality risk after an ovarian cancer diagnosis. Further investigation is warranted to evaluate whether postdiagnosis exposures are also associated with survival. IMPACT Given that pre- and postdiagnosis exposures are often correlated and many are modifiable, our study results can ultimately motivate the development of behavioral recommendations to enhance survival among patients with ovarian cancer.
Assuntos

Texto completo: 1 Coleções: 01-internacional Temas: Epidemiologia / Mortalidade / Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Carcinoma Epitelial do Ovário / Inflamação Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Middle aged Idioma: En Revista: Cancer Epidemiol Biomarkers Prev Assunto da revista: BIOQUIMICA / EPIDEMIOLOGIA / NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Temas: Epidemiologia / Mortalidade / Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Carcinoma Epitelial do Ovário / Inflamação Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Middle aged Idioma: En Revista: Cancer Epidemiol Biomarkers Prev Assunto da revista: BIOQUIMICA / EPIDEMIOLOGIA / NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article